Table 1. Patient characteristics.
| Control (n = 23) | Quiescent UC (n = 35) | Active UC (n = 66) | |
|---|---|---|---|
| Age, mean ± SD | 51.3 ± 13.8 | 42.6 ± 14.2a | 42.7 ± 15.1a |
| Gender | 39.1% Male | 42.9% Male | 45.5% Male |
| Body Mass Index, mean ± SD | 26.4 ± 9.5 | 27.6 ± 5.9 | 27.1 ± 7.3 |
| Tobacco Use | 2 (8.7%) | 3 (8.6%) | 4 (6.1%) |
| Any IBD Therapy | 1 (4.4%) | 34 (97.1%) | 62 (93.9%) |
| Any 5-ASA | 1 (4.4%)e | 28 (80.0%)c | 54 (81.8%)c |
| Corticosteroids | 0 | 4 (11.4%) | 11 (16.7%)a |
| Immunomodulators | 0 | 13 (37.1%)b | 19 (28.8%)b |
| Anti-TNF-α | 0 | 12 (25.3%)b | 10 (15.2%)a,d |
| Completed Dietary Interview | 17 (73.9%) | 24 (68.6%) | 49 (74.2%) |
UC status determined by histologic activity.
aP < 0.05,
bP < 0.01,
cP < 0.001 versus control;
dP < 0.05 versus quiescent UC.
eThis patient was started on therapy for presumed UC but was subsequently deemed to have irritable bowel syndrome.
Age and body mass index statistics were assessed by the Kruskal-Wallis test followed by the Mann-Whitney U test. Categorical data were analyzed using the Pearson’s χ2 test.